Aristeia Capital’s Caris Life Sciences CAI Stock Holding History

Aristeia Capital’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,383	Closed	-$438K	–	652
2025 Q2	$438K	Buy	+16,383	New	+$442K	0.01%	227

Other funds holding CAI

SSP

Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Aristeia Capital's CAI Position: Q3 2025 in Review

Aristeia Capital sold out of Caris Life Sciences (CAI) in Q3 2025, closing a stake of 16,383 shares — an estimated $438K sold.

Aristeia Capital first reported a position in CAI in Q2 2025 and held it in 1 quarter. The position peaked at $438K in Q2 2025. 138 funds tracked by Wall St. Rank hold CAI as of Q3 2025.

Aristeia Capital reported no remaining Caris Life Sciences position as of Q3 2025 after selling out during the quarter.
Aristeia Capital sold 16,383 Caris Life Sciences shares in Q3 2025, an estimated $438K.
Aristeia Capital first reported a position in Caris Life Sciences in Q2 2025 and held it in 1 quarter.
Aristeia Capital's Caris Life Sciences position peaked at $438K in Q2 2025.
138 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2025.

Based on Aristeia Capital's 13F filing for Q3 2025, filed 14 Nov 2025.